Liver diseases such as hepatitis, cirrhosis, and hepatocellular carcinoma are global health
problems accounting for approximately 800 million cases and over 2 million deaths per year …

Chronic liver diseases represent a global health problem due to their high prevalence
worldwide and the limited available curative treatment options. They can result from various …

Nonalcoholic steatohepatitis (NASH) is emerging as a leading cause of chronic liver
disease. However, therapeutic options are limited by incomplete understanding of the …

Aims The first-line treatment for advanced hepatocellular carcinoma (HCC) is the
multikinase inhibitor sorafenib (SOR). Sofafenib resistance is linked to protein kinase …

Liver diseases, particularly viral hepatitis, cirrhosis and hepatocellular carcinoma, are
common in clinical practice with high morbidity and mortality worldwide. Many substances …

Nanomedicine constitutes the emerging field of medical applications for nanotechnology
such as nanomaterial-based drug delivery systems. This technology may hold exceptional …

As hepatic stellate cells (HSCs) are essential for hepatic fibrogenesis, HSCs targeted nano-
drug delivery system is a research hotspot in liver fibrosis therapy. However, the excessive …

The cellular fate of nanoparticles in the liver is not fully understood. Because the
effectiveness and safety of nanoparticles in liver therapy depends on targeting nanoparticles …

Recent advancement in the field of synthesis and application of nanomaterials provided
holistic approach for both diagnosis as well as treatment of diseases. Briefly, three …

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that can lead to
end‐stage liver disease needing a liver transplant. Many pharmacological approaches are …